[New developments in grading of astrocytomas, IDH-mutant: Study of the impact of update 12 of cIMPACT-NOW].
INTRODUCTION The 2021 World Health Organisation (WHO) classification of the Central Nervous System tumors introduced, for the first time, a molecular biomarker (homozygous deletion of CDKN2A/B) into the grading of astrocytomas, IDH-mutant. Since then, the cIMPACT-NOW expert group has proposed a new prognostic algorithm...